BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 29, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 27, 2018
View Archived Issues
Vertex studies VX-659 triple combination in phase III cystic fibrosis study
Read More
Nektar initiates phase I/II study of NKTR-262 alone and in combination for solid tumor malignancies
Read More
AbbVie opens phase I trial of ABBV-744 in advanced prostate cancer and AML
Read More
Male contraceptive 11beta-MNTDC reduces testosterone in healthy male volunteers
Read More
Phase III efficacy and safety data reported for vibegron in overactive bladder
Read More
Phase III trials of rimegepant in migraine meet coprimary endpoints
Read More
Allecra reports phase II data on cefepime/AAI-101 in cUTI
Read More
Protagonist stops phase IIb study of PTG-100 for ulcerative colitis based on futility analysis
Read More
FDA grants breakthrough therapy designation to enfortumab vedotin
Read More
Loxo completes rolling NDA for larotrectinib in U.S.
Read More
Amag submits NDA for bremelanotide for hypoactive sexual desire disorder
Read More
EMA grants PRIME designation for lumasiran in primary hyperoxaluria type 1
Read More
Acorda submits MAA to EMA for Inbrija
Read More
EMA committee recommends approval of new dosing schedules for Opdivo in E.U.
Read More
Celgene tests new purine-based compound with antimalarial properties
Read More
FORMA Therapeutics establishes collaboration with Arpeggio Biosciences
Read More
Sanofi seeks U.S. and E.U. approval for sotagliflozin in type 1 diabetes
Read More
Vitaros end-of-review meeting scheduled by FDA
Read More
Japanese approval for Orkedia
Read More
Hemlibra approved in Japan
Read More
Hernicore approved in Japan to treat lumbar disc herniation
Read More
Bayer Pharma divluges new adenosine receptor A2B antagonists
Read More
Nippon Kayaku obtains Japanese approval for trastuzumab biosimilar
Read More
Jiangsu Hengrui Medicine Co., Shanghai Hengrui Pharmaceutical Co. patent factor XIa inhibitors
Read More
AdPueriVitam discovers novel NMDA receptor antagonists
Read More
Velcade approved in Japan for primary macroglobulinemia and lymphoplasmacytic lymphoma
Read More
Gilead identifies novel Toll-like receptor 8 modulators
Read More
RaQualia receives milestone payment from EA Pharma
Read More
New Toll-like receptor 7/8 agonists patented by GlaxoSmithKline
Read More
ACT-539313 safe and well tolerated in first-in-human study
Read More
